Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Gastroenterology. 2023 Jul;165(1):286-288.e4. doi: 10.1053/j.gastro.2023.02.042. Epub 2023 Mar 7.

Authors

Magdalena Espinoza¹, Maishara Muquith², Mir Lim², Hao Zhu², Amit G Singal¹, David Hsiehchen³

Affiliations

¹ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
² Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
³ Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: gbtwnow@gmail.com.

PMID: 36894034
DOI: 10.1053/j.gastro.2023.02.042

No abstract available

MeSH terms

Bevacizumab / adverse effects
Carcinoma, Hepatocellular* / drug therapy
Causality
Humans
Liver Neoplasms* / drug therapy

Substances

Bevacizumab
atezolizumab